In line with this prediction, we asked if the crosstalk between ER positive breast cancer cells and fibroblasts enhanced the resistance of tamoxifen and fulvestrant, which ultimately increased the endocrine resistant breast cancer cell growth and migration. The gene discussed is ESR1; the disease is breast carcinoma.